CN1946740B - 抗人腱生蛋白单克隆抗体 - Google Patents

抗人腱生蛋白单克隆抗体 Download PDF

Info

Publication number
CN1946740B
CN1946740B CN2005800061324A CN200580006132A CN1946740B CN 1946740 B CN1946740 B CN 1946740B CN 2005800061324 A CN2005800061324 A CN 2005800061324A CN 200580006132 A CN200580006132 A CN 200580006132A CN 1946740 B CN1946740 B CN 1946740B
Authority
CN
China
Prior art keywords
antibody
bottle
biotinylated
tenascin
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800061324A
Other languages
English (en)
Chinese (zh)
Other versions
CN1946740A (zh
Inventor
R·德圣蒂斯
A·佩利恰
G·帕隆博
P·卡尔米纳蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Sigg Ma Co
Original Assignee
Tecnogen SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnogen SpA filed Critical Tecnogen SpA
Publication of CN1946740A publication Critical patent/CN1946740A/zh
Application granted granted Critical
Publication of CN1946740B publication Critical patent/CN1946740B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2005800061324A 2004-02-27 2005-02-16 抗人腱生蛋白单克隆抗体 Expired - Fee Related CN1946740B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.
ITRM2004A000105 2004-02-27
PCT/IT2005/000078 WO2005082938A2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody

Publications (2)

Publication Number Publication Date
CN1946740A CN1946740A (zh) 2007-04-11
CN1946740B true CN1946740B (zh) 2012-09-05

Family

ID=34897820

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800061324A Expired - Fee Related CN1946740B (zh) 2004-02-27 2005-02-16 抗人腱生蛋白单克隆抗体

Country Status (15)

Country Link
US (1) US7989171B2 (enExample)
EP (1) EP1718678B1 (enExample)
JP (1) JP5191036B2 (enExample)
KR (1) KR101266389B1 (enExample)
CN (1) CN1946740B (enExample)
AR (1) AR047819A1 (enExample)
AU (1) AU2005217237B2 (enExample)
BR (1) BRPI0508082A8 (enExample)
CA (1) CA2558718C (enExample)
ES (1) ES2654065T3 (enExample)
IT (1) ITRM20040105A1 (enExample)
MX (1) MXPA06009674A (enExample)
PL (1) PL1718678T3 (enExample)
PT (1) PT1718678T (enExample)
WO (1) WO2005082938A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2012031084A (ja) * 2010-07-29 2012-02-16 Tokyo Univ Of Science 抗腫瘍剤
WO2014113459A1 (en) * 2013-01-15 2014-07-24 Duke University Hiv-1 neutralizing factor
EP2999967B1 (en) 2013-05-21 2020-05-20 NX Pharmagen Use of tenascin-c as an extracellular marker of tumor-derived microparticles
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN119019548B (zh) * 2022-07-05 2025-06-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355711A (zh) * 1999-02-01 2002-06-26 洛杉矶儿童医院 抑制脑肿瘤生长的方法
WO2003072608A1 (en) * 2002-02-26 2003-09-04 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Anti-human tenascin monoclonal antibody

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634076A (en) * 1994-10-04 1997-05-27 Analog Devices, Inc. DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer
US6014709A (en) * 1997-11-05 2000-01-11 Unisys Corporation Message flow protocol for avoiding deadlocks
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
AU4682100A (en) * 1999-05-01 2000-11-17 University Of Medicine And Dentistry Of New Jersey Neurite outgrowth and guidance by tenascin-c
US7058750B1 (en) * 2000-05-10 2006-06-06 Intel Corporation Scalable distributed memory and I/O multiprocessor system
JP3646159B2 (ja) * 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
ITRM20010079A1 (it) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1355711A (zh) * 1999-02-01 2002-06-26 洛杉矶儿童医院 抑制脑肿瘤生长的方法
WO2003072608A1 (en) * 2002-02-26 2003-09-04 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Anti-human tenascin monoclonal antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
US 6335014 B1,（第3栏，第6-10行和第4栏第38-42行）.

Also Published As

Publication number Publication date
WO2005082938A2 (en) 2005-09-09
HK1100848A1 (en) 2007-09-28
EP1718678B1 (en) 2017-10-11
WO2005082938A3 (en) 2005-12-15
AU2005217237A1 (en) 2005-09-09
KR101266389B1 (ko) 2013-05-28
CA2558718C (en) 2015-01-13
ES2654065T3 (es) 2018-02-12
ITRM20040105A1 (it) 2004-05-27
AU2005217237B2 (en) 2011-12-22
JP5191036B2 (ja) 2013-04-24
BRPI0508082A (pt) 2007-07-17
PL1718678T3 (pl) 2018-05-30
CN1946740A (zh) 2007-04-11
CA2558718A1 (en) 2005-09-09
KR20070002029A (ko) 2007-01-04
US7989171B2 (en) 2011-08-02
JP2008506355A (ja) 2008-03-06
MXPA06009674A (es) 2007-03-21
BRPI0508082A8 (pt) 2017-12-26
PT1718678T (pt) 2017-12-29
US20100297003A1 (en) 2010-11-25
AR047819A1 (es) 2006-02-22
EP1718678A2 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
US8048417B2 (en) Anti-human tenascin monoclonal antibody
EP1470146B1 (en) Antibodies against the muc18 antigen
US9765155B2 (en) Covalent disulfide-linked diabodies and uses thereof
JP2005538682A (ja) カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
JP2005514409A (ja) Ｍｕｃ１８抗原に対する抗体の使用
JP2022540611A (ja) Ｄｌｌ３をターゲッティングする抗体とその使用
US20240368269A1 (en) Anti-dll3 antibodies and uses thereof
CN107614530A (zh) 用于多发性骨髓瘤（mm）的治疗
CN1946740B (zh) 抗人腱生蛋白单克隆抗体
CN116574187A (zh) 针对gucy2c的抗体及其用途
HK1100848B (en) Anti-human tenascin monoclonal antibody
CN118324916A (zh) 一种抗人gprc5d的单克隆抗体及其制备方法和用途
Kobayashi et al. Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: Preinjection of intact antibody versus clearance of antigen with avidin-biotin system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1100848

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

Free format text: FORMER OWNER: TECNOGEN S. P. A.

Effective date: 20130308

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130308

Address after: Rome Italy

Patentee after: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A.

Address before: Pianardi Monteville, Italy

Patentee before: Tecnogen S. P. A.

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1100848

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20171207

Address after: Milan Italy

Patentee after: Alpha Sigg Ma Co.

Address before: Rome Italy

Patentee before: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120905

Termination date: 20200216

CF01 Termination of patent right due to non-payment of annual fee